OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Cardiology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-08-01 to 2024-08-01.)

Article	Citations
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	624
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	608
Interplay between inflammation and thrombosis in cardiovascular pathology	410
Smart wearable devices in cardiovascular care: where we are and how to move forward	376
PPAR control of metabolism and cardiovascular functions	370
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	368
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	354
Global epidemiology of dyslipidaemias	348
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	326
Epidemiology of cardiovascular disease in Europe	296
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	295
Pathophysiology of sepsis-induced cardiomyopathy	281
Global epidemiology of valvular heart disease	271
Transportation noise pollution and cardiovascular disease	246
Epicardial adipose tissue in contemporary cardiology	219
Self-powered cardiovascular electronic devices and systems	219
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	216
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	214
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	214
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	196
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	192
Cardiovascular disease in patients with severe mental illness	186
Ceramides and other sphingolipids as drivers of cardiovascular disease	185
The role of cardiac rehabilitation in improving cardiovascular outcomes	183
Heart failure with mid-range or mildly reduced ejection fraction	179

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	170
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	158
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	155
Lifestyle interventions for the prevention and treatment of hypertension	153
Systems biology in cardiovascular disease: a multiomics approach	153
Optical coherence tomography in coronary atherosclerosis assessment and intervention	150
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	146
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	139
Sit less and move more for cardiovascular health: emerging insights and opportunities	138
Epidemiology of the inherited cardiomyopathies	136
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	128
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	126
Vascular endothelial cell development and diversity	116
Transforming growth factor-β in myocardial disease	115
Genomics of hypertension: the road to precision medicine	115
Blood pressure and its variability: classic and novel measurement techniques	111
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	109
High-density lipoproteins, reverse cholesterol transport and atherogenesis	107
Mechanisms and consequences of endothelial cell senescence	106
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	106
Genomic frontiers in congenital heart disease	105
Cardiac optogenetics: a decade of enlightenment	105
Catheter ablation for atrial fibrillation: current indications and evolving technologies	103
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	101
Apolipoproteins in vascular biology and atherosclerotic disease	101
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	95
Epidemiology and prevention of venous thromboembolism	95
Climate change and cardiovascular disease: implications for global health	90
Applications of artificial intelligence in cardiovascular imaging	90
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	89
The role of mitochondrial fission in cardiovascular health and disease	89
Cardiovascular risks of climate change	88
Obesity and the risk of cardiometabolic diseases	87
Epidemiology and modifiable risk factors for atrial fibrillation	84
Update on the pathophysiology and medical treatment of peripheral artery disease	84
Sulfide regulation of cardiovascular function in health and disease	84
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	82
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	82
RNA-targeting and gene editing therapies for transthyretin amyloidosis	82
Branched-chain amino acids in cardiovascular disease	81
Myocardial stunning and hibernation revisited	80
Cardiac involvement in the long-term implications of COVID-19	80
Bleeding avoidance strategies in percutaneous coronary intervention	76
Clinical utility of polygenic risk scores for coronary artery disease	75
Social determinants of atrial fibrillation	72
A fresh look at coronary microembolization	72
Prevention of atherosclerosis from childhood	71